Method of treating retinopathy of prematurity using somatostatin analogs

• US 20030207811A1
• Filed: 05/03/2002
• Published: 11/06/2003
• Est. Priority Date: 05/03/2002
• Status: Abandoned Application

• Current Assignee: Georgetown University Of Wash. D.C., Oakwood Laboratories LLC
• Original Assignee: Georgetown University Of Wash. D.C., Oakwood Laboratories LLC
• Inventors: Schrier, Bruce K., Higgins, Rosemary D.
• Application Number:
  US10/138,554
• Publication Number:
  US 20030207811A1
• Time in Patent Office: Days
• US Class Current: 514/16
• CPC Class Codes: A61K 38/31 Somatostatins

Abstract

The present invention discloses methods of treating or preventing retinopathy of prematurity in neonatal mammals involving the use of an amount of a somatostatin analog containing composition sufficient to provide a therapeutic benefit without affecting growth of the neonates.

Claims

1. A method of treating or preventing retinopathy of prematurity in a neonatal mammal comprising the step of administering to the mammal, an amount of a somatostatin analog containing composition sufficient to provide a therapeutic benefit.

2. The method of claim 1, wherein the somatostatin analog is octreotide, Woc4D, a somatostatin analog having a serum half-life of octreotide, a somatostatin analog having a serum half-life more than that of octreotide or a somatostatin analog having a serum half-life of Woc4D.

3. The method of claim 1, wherein the somatostatin analog is octreotide or a somatostatin analog having an ability to alter pituitary growth hormone expression similar to that of said octreotide.

4. The method of claim 1, wherein the somatostatin analog is Woc-4D or a somatostatin analog having an ability to alter pituitary growth hormone expression similar to that of said Woc-4D.

5. The method of claim 1, wherein the somatostatin analog is selected from the group consisting of octreotide, lanreotide (LANREOTIDE™

), Vapreotide, Woc-2A, Woc-2B, Woc-3A, Woc-3B, Woc-4, Woc-4D, Woc-5 and Woc-8.

6. The method of claim 5, wherein said composition is administered subcutaneously.

7. The method of claim 6, wherein said mammal is a mouse or a human.

8. The method of claim 7, wherein said mammal is the human.

9. The method of claim 8, wherein the somatostatin analog is octreotide.

10. The method of claim 9, wherein octreotide containing composition is administered two or more times daily before, during, and/or after administration of supplemental oxygen to said mammal in doses sufficient to bring about suppression of retinopathy of prematurity.

11. The method of claim 8, wherein the somatostatin analog is Woc-4D.

12. The method of claim 11, wherein Woc4D containing composition is administered two or more times daily before, during, and/or after administration of supplemental oxygen to said mammal in doses sufficient to bring about suppression of retinopathy of prematurity.

13. A method of treating or preventing retinopathy of prematurity comprising the step of administering to a mammal in need thereof an amount of a composition comprising a somatostatin analog and a pharmaceutically acceptable carrier sufficient to provide a therapeutic benefit wherein the somatostatin analog is selected from the group consisting of octreotide and Woc-4D.

14. The method of claim 13, wherein the pharmaceutically acceptable carrier is a buffer soluation.

15. The method of claim 14, wherein said mammal is a mouse or a human.

16. The method of claim 15, wherein said mammal is the human.

17. The method of claim 16, wherein the selected somatostatin analog is octreotide.

18. The method of claim 17, wherein the selected somatostatin analog is Woc-4D.

19. A method of preventing retinopathy of prematurity in a neonatal human comprising the step of administering to said human, an amount of an octreotide or Woc-4D containing composition sufficient to provide a therapeutic benefit.

20. The method of claim 19, wherein the somatostatin analog is octreotide, Woc4D, a somatostatin analog having a serum half-life of octreotide, a somatostatin analog having a serum half-life more than that of octreotide or a somatostatin analog having a serum half-life of Woc4D.

21. The method of claim 19, wherein the somatostatin analog is octreotide or a somatostatin analog having an ability to alter pituitary growth hormone expression similar to that of the octreotide.

22. The method of claim 19, wherein the somatostatin analog is Woc-4D or a somatostatin analog having an ability to alter pituitary growth hormone expression similar to that of the Woc-4D.

23. The method of claim 19, wherein the somatostatin analog is selected from the group consisting of octreotide, lanreotide (LANREOTIDE™

), Vapreotide, Woc-2A, Woc-2B, Woc-3A, Woc-3B, Woc-4, Woc-4D, Woc-5 and Woc-8.

24. The method of claim 23, wherein said composition is administered subcutaneously.

25. The method of claim 24, wherein the composition contains Woc-4D.

26. The method of claim 25, wherein the composition is administered one or more times daily before, during, and/or after administration of supplemental oxygen to said mammal in doses sufficient to bring about suppression of retinopathy of prematurity.

27. The method of claim 24, wherein the composition contains octreotide.

28. The method of claim 27, wherein the composition is administered two or more times daily before, during, and/or after administration of supplemental oxygen to said mammal in doses sufficient to bring about suppression of retinopathy of prematurity.

29. A method of preventing retinopathy of prematurity in a neonatal human comprising the step of subcutaneously administering to the human, an amount of an octreotide or Woc-4D containing composition sufficient to provide a therapeutic benefit.

30. The method of claim 29, wherein the somatostatin analog is octreotide, Woc4D, a somatostatin analog having a serum half-life of octreotide, a somatostatin analog having a serum half-life more than that of octreotide or a somatostatin analog having a serum half-life of Woc4D.

31. The method of claim 29, wherein the somatostatin analog is octreotide or a somatostatin analog having an ability to alter pituitary growth hormone expression similar to that of the octreotide.

32. The method of claim 29, wherein the somatostatin analog is Woc-4D or a somatostatin analog having an ability to alter pituitary growth hormone expression similar to that of the Woc-4D.

33. The method of claim 29, wherein the somatostatin analog is selected from the group consisting of octreotide, lanreotide (LANREOTIDE™

), Vapreotide, Woc-2A, Woc-2B, Woc-3A, Woc-3B, Woc-4, Woc-4D, Woc-5 and Woc-8.

34. The method of claim 33, wherein said composition is administered subcutaneously.

35. A method of treating or preventing retinopathy of prematurity comprising the step of administering to a mammal in need thereof a composition comprising an amount of somatostatin analog and a pharmaceutically acceptable carrier sufficient to provide a therapeutic benefit wherein the somatostatin analog is octreotide.

36. The method of claim 35, wherein said composition is administered subcutaneously.

37. The method of claim 36, wherein said mammal is a human.

38. The method of claim 37, wherein said composition is a controlled-release composition.

39. A method of treating or preventing retinopathy of prematurity comprising the step of administering to a mammal in need thereof a composition comprising an amount of somatostatin analog and a pharmacetically acceptable carrier sufficient to provide a therapeutic benefit wherein the somatostatin analog is Woc-4D.

40. The method of claim 39, wherein said composition is administered subcutaneously.

41. The method of claim 40, wherein said mammal is a human.

42. The method of claim 41, wherein said composition is a controlled-release composition.

43. A pharmaceutical composition Woc-4D and a pharmaceutically acceptable carrier for treating or preventing retinopathy of prematurity in a neonatal mammal.